查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1298348

宮頸癌診斷市場：按類型、年齡組：2023-2032年全球機會分析和行業預測

Cervical Cancer Diagnostic Market By Type (Pap Smear Tests, HPV test, Biopsy and ECC, Colposcopy Tests, Others), By Age group (20 to 40 years, above 40 years): Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 228 Pages | 商品交期: 2-3個工作天內

價格

2022 年，全球宮頸癌診斷市場價值為 78 億美元，預計到 2032 年將達到 126 億美元，2023 年至 2032 年復合年增長率為 5%。

宮頸癌診斷市場-IMG1

宮頸癌是一種在子宮頸任何部位形成的癌症。 子宮頸是陰道和子宮（子宮）之間的開口。 它是生殖系統的一部分，有時稱為子宮頸。 幾乎所有宮頸癌都是由一種人乳頭瘤病毒 (HPV) 感染引起的。 儘管宮頸癌始於具有癌前期變化（癌前期）的細胞，但只有一些患有癌前期宮頸的女性才會患上癌症。 對於大多數女性來說，癌前細胞無需任何治療即可消失。 然而，在一些女性中，癌前病變會轉變為真正的（侵襲性）癌症。 治療宮頸癌前期可以預防幾乎所有宮頸癌。 宮頸癌篩查的目的是在可以治療或治癒的早期階段發現癌前或癌性癌症。 定期檢查可以預防宮頸癌並挽救生命。 宮頸癌篩查測試包括 HPV 測試和巴氏塗片測試。

宮頸癌診斷市場的增長是由研發活動增加、宮頸癌患病率上升、政府和私營機構產品開發支出激增以及診斷測試產品技術進步推動的。增加去醫院進行癌症篩查的次數。 例如，根據美國疾病控制與預防中心（CDC）2022年8月發布的數據，美國每年約有13,000名女性新診斷出患有宮頸癌，約4,000名女性死於該癌症。 2019 年，當美國有發病率數據時，每 10 萬名女性報告有 8 例新發宮頸癌病例，其中 2 名女性死於該癌症。

此外，診斷研究實驗室不斷增加的研究渠道以及人們對更嚴格癌症篩查的認識不斷增強也促進了市場的增長。 例如，根據世界衛生組織 (WHO) 的數據，一月被慶祝為宮頸癌宣傳月。 現在是提高人們對宮頸癌和 HPV 疫苗接種認識的好時機。 消除宮頸癌也是宮頸癌宣傳月的主題。 然而，HPV 疫苗的可用性、不准確的子宮頸抹片檢查和其他類型的宮頸癌篩查預計將阻礙市場的增長。

內容

第1章簡介

第 2 章執行摘要

第3章市場概述

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態
    • 驅動程序
      • 宮頸癌患病率不斷上升
      • HPV 感染患者增加
      • 不安全性行為激增
    • 阻礙因素
      • 宮頸癌替代診斷方法的可用性
    • 機會
      • 肥胖人數激增
  • COVID-19 對市場的影響分析

第 4 章宮頸癌診斷市場：按類型

  • 概述
    • 市場規模和預測
  • 子宮頸抹片檢查
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • HPV檢測
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 活檢和 ECC
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 陰道鏡檢查
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第5章宮頸癌診斷市場：按年齡組

  • 概述
    • 市場規模和預測
  • 20-40歲
    • 主要市場趨勢、增長因素和機遇
    • 按地區劃分的市場規模和預測
    • 市場份額分析：按國家/地區劃分
  • 40多年
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第6章宮頸癌診斷市場：按地區

  • 概述
    • 市場規模/預測：按地區劃分
  • 北美
    • 主要趨勢和機遇
    • 市場規模/預測：按類型
    • 市場規模/預測：按年齡段劃分
    • 市場規模/預測：按國家/地區劃分
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
  • 歐洲
    • 主要趨勢和機遇
    • 市場規模/預測：按類型
    • 市場規模/預測：按年齡段劃分
    • 市場規模/預測：按國家/地區劃分
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
      • 歐洲其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
  • 亞太地區
    • 主要趨勢和機遇
    • 市場規模/預測：按類型
    • 市場規模/預測：按年齡段劃分
    • 市場規模/預測：按國家/地區劃分
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
      • 亞太地區其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機遇
    • 市場規模/預測：按類型
    • 市場規模/預測：按年齡段劃分
    • 市場規模/預測：按國家/地區劃分
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分
      • 其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模/預測：按年齡段劃分

第7章競爭格局

  • 簡介
  • 關鍵成功策略
  • 10家主要公司的產品圖譜
  • 競賽儀表板
  • 比賽熱圖
  • 2022 年頂級公司定位

第8章公司簡介

  • Abbott Laboratories
  • Qaigen NV
  • Carl Zeiss AG
  • Thermo Fisher Scientific Inc.
  • Becton, Dickinson and Company
  • Hologic Inc.
  • F. Hoffmann-La Roche AG
  • CooperSurgical Inc.
  • Siemens Healthineers
  • Dysis Medical ltd.
Product Code: A00304

The Global Cervical Cancer Diagnostic Market valued for $7.8 billion in 2022 and is estimated to reach $12.6 billion by 2032, exhibiting a CAGR of 5% from 2023 to 2032.

Cervical Cancer Diagnostic Market - IMG1

Cervical cancer is a type of cancer found anywhere in the cervix. The cervix is the opening between the vagina and the womb (uterus). It is part of the reproductive system and is sometimes called the neck of the womb. Nearly all cervical cancers are caused by an infection from certain types of human papillomavirus (HPV). Although cervical cancers start from cells with pre-cancerous changes (pre-cancers), only some of the women with pre-cancers of the cervix will develop cancer. For most women, pre-cancerous cells will go away without any treatment. But, in some women pre-cancers turn into true (invasive) cancers. Treating cervical pre-cancers can prevent almost all cervical cancers. The goal of cervical cancer screening is to find pre-cancer or cancer early when it is more treatable and curable. Regular screening can prevent cervical cancers and save lives. The tests for cervical cancer screening are HPV test and the Pap test.

The growth of the cervical cancer diagnostic market is driven by increase in number of research and development activities, rise in prevalence of cervical cancer, surge in expenditure on the product development by the government and private organizations and increase in the technological advancements of the diagnostics tests products and increase the number of hospital visits of the patients for cancer screening. For instance, according to the data by the Centers of Disease Control and Prevention (CDC), published in August 2022, about 13,000 new cases of cervical cancer are diagnosed and about 4,000 women died due to this cancer each year in the U.S. Similarly, 12,795 new cases of cervical cancer were reported among women, and 4,152 women died of this cancer. For every 100,000 women, 8 new cervical cancer cases were reported, and 2 women died of this cancer in 2019, the year for which incidence data was available in the U.S.

Moreover, increase in research pipeline among the diagnostic research organizations and rise in awareness about strictness in the cancer screening also helps in the growth of the market. For instance, according to the data of the World Health Organization (WHO), January is celebrated as Cervical Cancer Awareness Month. It gives a perfect opportunity for World Health Organization and partners to raise awareness about cervical cancer and HPV vaccination. It also focuses on the elimination of cervical cancer as the theme for its Cervical Cancer Awareness Month. However, HPV vaccination, inaccurate pap smear testing and the availability of other types of screening of cervical cancer are expected to hinder the growth of the market.

The cervical cancer diagnostic market is segmented on the basis of type, age group and region. On the basis of type, the market is categorized into pap smear tests, HPV test, biopsy and ECC, colposcopy tests and others. On the basis of age group, the market is classified into 20 to 40 years, and above 40 years. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major companies profiled in the report include: Abbott Laboratories, Qaigen NV, Carl Zeiss AG, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Hologic Inc, F. Hoffmann-La Roche AG, Siemens Healthineers, CooperSurgical Inc., and Dysis Medical ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global cervical cancer diagnostic market analysis from 2022 to 2032 to identify the prevailing global cervical cancer diagnostic market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global cervical cancer diagnostic market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global global cervical cancer diagnostic market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Pap Smear Tests
  • HPV test
  • Biopsy and ECC
  • Colposcopy Tests
  • Others

By Age group

  • 20 to 40 years
  • above 40 years

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Carl Zeiss AG
  • CooperSurgical Inc.
  • Dysis Medical ltd.
  • F. Hoffmann-La Roche AG
  • Hologic Inc.
  • Qaigen NV
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in the prevalence of cervical cancer
      • 3.4.1.2. Increase in number of patients suffering from HPV infection
      • 3.4.1.3. Surge in incidences of unsafe sex
    • 3.4.2. Restraints
      • 3.4.2.1. Availability of alternative diagnosis methods of cervical cancer
    • 3.4.3. Opportunities
      • 3.4.3.1. Surge in prevalence of obesity
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Pap Smear Tests
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. HPV test
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Biopsy and ECC
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Colposcopy Tests
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Others
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. 20 to 40 years
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. above 40 years
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key trends and opportunities
    • 6.2.2. Market size and forecast, by Type
    • 6.2.3. Market size and forecast, by Age group
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Key market trends, growth factors and opportunities
      • 6.2.4.1.2. Market size and forecast, by Type
      • 6.2.4.1.3. Market size and forecast, by Age group
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Key market trends, growth factors and opportunities
      • 6.2.4.2.2. Market size and forecast, by Type
      • 6.2.4.2.3. Market size and forecast, by Age group
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Key market trends, growth factors and opportunities
      • 6.2.4.3.2. Market size and forecast, by Type
      • 6.2.4.3.3. Market size and forecast, by Age group
  • 6.3. Europe
    • 6.3.1. Key trends and opportunities
    • 6.3.2. Market size and forecast, by Type
    • 6.3.3. Market size and forecast, by Age group
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Key market trends, growth factors and opportunities
      • 6.3.4.1.2. Market size and forecast, by Type
      • 6.3.4.1.3. Market size and forecast, by Age group
      • 6.3.4.2. France
      • 6.3.4.2.1. Key market trends, growth factors and opportunities
      • 6.3.4.2.2. Market size and forecast, by Type
      • 6.3.4.2.3. Market size and forecast, by Age group
      • 6.3.4.3. UK
      • 6.3.4.3.1. Key market trends, growth factors and opportunities
      • 6.3.4.3.2. Market size and forecast, by Type
      • 6.3.4.3.3. Market size and forecast, by Age group
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Key market trends, growth factors and opportunities
      • 6.3.4.4.2. Market size and forecast, by Type
      • 6.3.4.4.3. Market size and forecast, by Age group
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Key market trends, growth factors and opportunities
      • 6.3.4.5.2. Market size and forecast, by Type
      • 6.3.4.5.3. Market size and forecast, by Age group
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Key market trends, growth factors and opportunities
      • 6.3.4.6.2. Market size and forecast, by Type
      • 6.3.4.6.3. Market size and forecast, by Age group
  • 6.4. Asia-Pacific
    • 6.4.1. Key trends and opportunities
    • 6.4.2. Market size and forecast, by Type
    • 6.4.3. Market size and forecast, by Age group
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. China
      • 6.4.4.1.1. Key market trends, growth factors and opportunities
      • 6.4.4.1.2. Market size and forecast, by Type
      • 6.4.4.1.3. Market size and forecast, by Age group
      • 6.4.4.2. Japan
      • 6.4.4.2.1. Key market trends, growth factors and opportunities
      • 6.4.4.2.2. Market size and forecast, by Type
      • 6.4.4.2.3. Market size and forecast, by Age group
      • 6.4.4.3. India
      • 6.4.4.3.1. Key market trends, growth factors and opportunities
      • 6.4.4.3.2. Market size and forecast, by Type
      • 6.4.4.3.3. Market size and forecast, by Age group
      • 6.4.4.4. Australia
      • 6.4.4.4.1. Key market trends, growth factors and opportunities
      • 6.4.4.4.2. Market size and forecast, by Type
      • 6.4.4.4.3. Market size and forecast, by Age group
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Key market trends, growth factors and opportunities
      • 6.4.4.5.2. Market size and forecast, by Type
      • 6.4.4.5.3. Market size and forecast, by Age group
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Key market trends, growth factors and opportunities
      • 6.4.4.6.2. Market size and forecast, by Type
      • 6.4.4.6.3. Market size and forecast, by Age group
  • 6.5. LAMEA
    • 6.5.1. Key trends and opportunities
    • 6.5.2. Market size and forecast, by Type
    • 6.5.3. Market size and forecast, by Age group
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Key market trends, growth factors and opportunities
      • 6.5.4.1.2. Market size and forecast, by Type
      • 6.5.4.1.3. Market size and forecast, by Age group
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Key market trends, growth factors and opportunities
      • 6.5.4.2.2. Market size and forecast, by Type
      • 6.5.4.2.3. Market size and forecast, by Age group
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Key market trends, growth factors and opportunities
      • 6.5.4.3.2. Market size and forecast, by Type
      • 6.5.4.3.3. Market size and forecast, by Age group
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Key market trends, growth factors and opportunities
      • 6.5.4.4.2. Market size and forecast, by Type
      • 6.5.4.4.3. Market size and forecast, by Age group

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. Abbott Laboratories
    • 8.1.1. Company overview
    • 8.1.2. Key Executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
  • 8.2. Qaigen NV
    • 8.2.1. Company overview
    • 8.2.2. Key Executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
  • 8.3. Carl Zeiss AG
    • 8.3.1. Company overview
    • 8.3.2. Key Executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
  • 8.4. Thermo Fisher Scientific Inc.
    • 8.4.1. Company overview
    • 8.4.2. Key Executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
  • 8.5. Becton, Dickinson and Company
    • 8.5.1. Company overview
    • 8.5.2. Key Executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Hologic Inc.
    • 8.6.1. Company overview
    • 8.6.2. Key Executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
    • 8.6.7. Key strategic moves and developments
  • 8.7. F. Hoffmann-La Roche AG
    • 8.7.1. Company overview
    • 8.7.2. Key Executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
    • 8.7.7. Key strategic moves and developments
  • 8.8. CooperSurgical Inc.
    • 8.8.1. Company overview
    • 8.8.2. Key Executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
  • 8.9. Siemens Healthineers
    • 8.9.1. Company overview
    • 8.9.2. Key Executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
  • 8.10. Dysis Medical ltd.
    • 8.10.1. Company overview
    • 8.10.2. Key Executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 02. CERVICAL CANCER DIAGNOSTIC MARKET FOR PAP SMEAR TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. CERVICAL CANCER DIAGNOSTIC MARKET FOR HPV TEST, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. CERVICAL CANCER DIAGNOSTIC MARKET FOR BIOPSY AND ECC, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. CERVICAL CANCER DIAGNOSTIC MARKET FOR COLPOSCOPY TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. CERVICAL CANCER DIAGNOSTIC MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 08. CERVICAL CANCER DIAGNOSTIC MARKET FOR 20 TO 40 YEARS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. CERVICAL CANCER DIAGNOSTIC MARKET FOR ABOVE 40 YEARS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 14. U.S. CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 15. U.S. CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 16. CANADA CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 17. CANADA CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 19. MEXICO CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE CERVICAL CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 23. GERMANY CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 24. GERMANY CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 25. FRANCE CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 26. FRANCE CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 27. UK CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 28. UK CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 29. ITALY CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 30. ITALY CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 31. SPAIN CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 32. SPAIN CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 33. REST OF EUROPE CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 34. REST OF EUROPE CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC CERVICAL CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 38. CHINA CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 39. CHINA CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 40. JAPAN CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 41. JAPAN CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 42. INDIA CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. INDIA CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 44. AUSTRALIA CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 45. AUSTRALIA CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 47. SOUTH KOREA CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 48. REST OF ASIA-PACIFIC CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 49. REST OF ASIA-PACIFIC CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 50. LAMEA CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 51. LAMEA CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 52. LAMEA CERVICAL CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. BRAZIL CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 54. BRAZIL CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 55. SAUDI ARABIA CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 56. SAUDI ARABIA CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 57. SOUTH AFRICA CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 58. SOUTH AFRICA CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 59. REST OF LAMEA CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 60. REST OF LAMEA CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 61. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 62. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 63. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 64. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 65. QAIGEN NV: KEY EXECUTIVES
  • TABLE 66. QAIGEN NV: COMPANY SNAPSHOT
  • TABLE 67. QAIGEN NV: PRODUCT SEGMENTS
  • TABLE 68. QAIGEN NV: PRODUCT PORTFOLIO
  • TABLE 69. CARL ZEISS AG: KEY EXECUTIVES
  • TABLE 70. CARL ZEISS AG: COMPANY SNAPSHOT
  • TABLE 71. CARL ZEISS AG: PRODUCT SEGMENTS
  • TABLE 72. CARL ZEISS AG: PRODUCT PORTFOLIO
  • TABLE 73. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 74. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 75. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
  • TABLE 76. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 77. BECTON, DICKINSON AND COMPANY: KEY EXECUTIVES
  • TABLE 78. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • TABLE 79. BECTON, DICKINSON AND COMPANY: PRODUCT SEGMENTS
  • TABLE 80. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 81. BECTON, DICKINSON AND COMPANY: KEY STRATERGIES
  • TABLE 82. HOLOGIC INC.: KEY EXECUTIVES
  • TABLE 83. HOLOGIC INC.: COMPANY SNAPSHOT
  • TABLE 84. HOLOGIC INC.: PRODUCT SEGMENTS
  • TABLE 85. HOLOGIC INC.: PRODUCT PORTFOLIO
  • TABLE 86. HOLOGIC INC.: KEY STRATERGIES
  • TABLE 87. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
  • TABLE 88. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 89. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS
  • TABLE 90. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 91. F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES
  • TABLE 92. COOPERSURGICAL INC.: KEY EXECUTIVES
  • TABLE 93. COOPERSURGICAL INC.: COMPANY SNAPSHOT
  • TABLE 94. COOPERSURGICAL INC.: PRODUCT SEGMENTS
  • TABLE 95. COOPERSURGICAL INC.: PRODUCT PORTFOLIO
  • TABLE 96. SIEMENS HEALTHINEERS: KEY EXECUTIVES
  • TABLE 97. SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
  • TABLE 98. SIEMENS HEALTHINEERS: PRODUCT SEGMENTS
  • TABLE 99. SIEMENS HEALTHINEERS: PRODUCT PORTFOLIO
  • TABLE 100. DYSIS MEDICAL LTD.: KEY EXECUTIVES
  • TABLE 101. DYSIS MEDICAL LTD.: COMPANY SNAPSHOT
  • TABLE 102. DYSIS MEDICAL LTD.: PRODUCT SEGMENTS
  • TABLE 103. DYSIS MEDICAL LTD.: PRODUCT PORTFOLIO
  • TABLE 104. DYSIS MEDICAL LTD.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN CERVICAL CANCER DIAGNOSTIC MARKET (2023-2032)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCERVICAL CANCER DIAGNOSTIC MARKET
  • FIGURE 10. CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CERVICAL CANCER DIAGNOSTIC MARKET FOR PAP SMEAR TESTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CERVICAL CANCER DIAGNOSTIC MARKET FOR HPV TEST, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CERVICAL CANCER DIAGNOSTIC MARKET FOR BIOPSY AND ECC, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CERVICAL CANCER DIAGNOSTIC MARKET FOR COLPOSCOPY TESTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CERVICAL CANCER DIAGNOSTIC MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2022(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CERVICAL CANCER DIAGNOSTIC MARKET FOR 20 TO 40 YEARS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CERVICAL CANCER DIAGNOSTIC MARKET FOR ABOVE 40 YEARS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. CERVICAL CANCER DIAGNOSTIC MARKET BY REGION, 2022
  • FIGURE 20. U.S. CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 21. CANADA CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. MEXICO CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. GERMANY CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. FRANCE CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. UK CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. ITALY CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. SPAIN CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. REST OF EUROPE CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. CHINA CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. JAPAN CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. INDIA CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. AUSTRALIA CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. SOUTH KOREA CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. REST OF ASIA-PACIFIC CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. BRAZIL CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SAUDI ARABIA CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SOUTH AFRICA CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF LAMEA CERVICAL CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 43. COMPETITIVE DASHBOARD
  • FIGURE 44. COMPETITIVE HEATMAP: CERVICAL CANCER DIAGNOSTIC MARKET
  • FIGURE 45. TOP PLAYER POSITIONING, 2022
  • FIGURE 46. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. ABBOTT LABORATORIES: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
  • FIGURE 48. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 49. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 50. QAIGEN NV: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 51. QAIGEN NV: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 52. QAIGEN NV: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 53. CARL ZEISS AG: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. CARL ZEISS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. CARL ZEISS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. THERMO FISHER SCIENTIFIC INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 57. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 58. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 59. BECTON, DICKINSON AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. BECTON, DICKINSON AND COMPANY: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. BECTON, DICKINSON AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. HOLOGIC INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. HOLOGIC INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 64. HOLOGIC INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 65. F. HOFFMANN-LA ROCHE AG: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 66. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 67. COOPERSURGICAL INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 68. COOPERSURGICAL INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 69. COOPERSURGICAL INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 70. SIEMENS HEALTHINEERS: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 71. SIEMENS HEALTHINEERS: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 72. SIEMENS HEALTHINEERS: REVENUE SHARE BY REGION, 2021 (%)